4-苯并咪唑-1-苯甲酰胺 | 220495-55-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 4-苯并咪唑-1-苯甲酰胺
• 英文名称: 4-(1H-benzo[d]imidazol-1-yl)benzenamide
• 英文别名: 4-(1H-benzo[d]imidazol-1-yl)phenylcarboxamide；4-(1H-benzo[d]imidazol-1-yl)benzamide；4-Benzoimidazol-1-yl-benzamide；4-(benzimidazol-1-yl)benzamide
• CAS: 220495-55-6
• 化学式: C₁₄H₁₁N₃O
• mdl: MFCD08437159
• 分子量: 237.261
• InChiKey: NABMFKHQADUPDB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  60.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-苯并咪唑-1-苯甲酰胺 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 以11 g的产率得到4-(1H-benzo[d]imidazol-1-yl)phenylmethylamine
  参考文献：
  名称：

  一种1位取代苯并咪唑衍生物的制备方法

  摘要：

  本发明公开了一种1位取代苯并咪唑衍生物4-(1H-苯并[d]咪唑-1-基)苯基甲胺的制备方法，以4-氟苯甲酸为起始原料，经过酯化、缩合、酰胺化、还原反应得到目标产物，该化合物是重要的医药中间体。

  公开号：

  CN104447567B
• 作为产物：
  描述：

  methyl 4-(1H-benzo[d]imidazol-1-yl)phenyl carboxylic acid 在 ammonium hydroxide 作用下， 反应 3.0h， 以21 g的产率得到4-苯并咪唑-1-苯甲酰胺
  参考文献：
  名称：

  一种1位取代苯并咪唑衍生物的制备方法

  摘要：

  本发明公开了一种1位取代苯并咪唑衍生物4-(1H-苯并[d]咪唑-1-基)苯基甲胺的制备方法，以4-氟苯甲酸为起始原料，经过酯化、缩合、酰胺化、还原反应得到目标产物，该化合物是重要的医药中间体。

  公开号：

  CN104447567B

文献信息

• THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Regents of the University of Minnesota

  公开号：US20200339555A1

  公开（公告）日：2020-10-29

  The invention provides a compound of formula I: or a salt thereof, wherein R 1 , R 2 , R 3 , A and n have any of the values described in the specification, as well as compositions comprising a compound of formula I, and methods of preparing and use thereof. The compounds are useful as vaccine adjuvant potentiators.

  该发明提供了化合物I的化学式，或其盐，其中R1、R2、R3、A和n具有规范中描述的任何值，以及包含化合物I的组合物，以及其制备和使用方法。这些化合物可用作疫苗佐剂增强剂。
• UREA COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF
  申请人：Ancureall Pharmaceutical (Shanghai) Co., Ltd.

  公开号：EP3424924A1

  公开（公告）日：2019-01-09

  Provided are a urea compound represented by general formula (I), a pharmaceutically acceptable salt thereof, a preparation method therefor, and use thereof as an FLT3 tyrosine protein kinase inhibitor, particularly in the prevention and/or treating of cancer.

  本发明提供了通式（I）代表的脲化合物、其药学上可接受的盐、其制备方法，以及其作为FLT3酪氨酸蛋白激酶抑制剂的用途，特别是在预防和/或治疗癌症中的用途。
• Urea compound, preparation method therefor and medical use thereof
  申请人：Ancureall Pharmaceutical (Shanghai) Co., Ltd.

  公开号：US10647680B2

  公开（公告）日：2020-05-12

  Provided are a urea compound represented by general formula (I), a pharmaceutically acceptable salt thereof, a preparation method therefor, and use thereof as an FLT3 tyrosine protein kinase inhibitor, particularly in the prevention and/or treating of cancer.

  本发明提供了通式（I）代表的脲化合物、其药学上可接受的盐、其制备方法，以及其作为FLT3酪氨酸蛋白激酶抑制剂的用途，特别是在预防和/或治疗癌症中的用途。
• Structure−Activity Relationships for 1-Phenylbenzimidazoles as Selective ATP Site Inhibitors of the Platelet-Derived Growth Factor Receptor
  作者：Brian D. Palmer、Jeff B. Smaill、Maruta Boyd、Diane H. Boschelli、Annette M. Doherty、James M. Hamby、Sonya S. Khatana、James B. Kramer、Alan J. Kraker、Robert L. Panek、Gina H. Lu、Tawny K. Dahring、R. Thomas Winters、H. D. Hollis Showalter、William A. Denny

  DOI：10.1021/jm9804681

  日期：1998.12.1

  1-Phenylbenzimidazoles are shown to be a new class of ATP-site inhibitors of the platelet-derived growth factor receptor (PDGFR). Structure-activity relationships (SARs) are narrow, with closely related heterocycles being inactive. A systematic study of substituted 1-phenyl-benzimidazoles showed clear SARs. Substituents at the 4'- and 3'-positions of the phenyl ring are tolerated but do not significantly improve activity, while substituents at the 2'-position abolish it. Substituents in the 2-, 4-, and 7-positions of the benzimidazole ring (with the exception of 4-OH) also abolish activity. Most substituents at the 5- and B-positions maintain or increase activity, with the 5-OH, 5-OMe, 5-COMe, and 5-CO2Me analogues being >10-fold more potent than the parent 1-phenylbenzimidazole. The 5-OMe analogue was both the most potent inhibitor, and showed the highest selectivity (50-fold) between PDGFR and FGFR isolated enzymes, and also a moderately effective inhibitor (IC50 = 1.9 mu M) of PDGF-stimulated PDGFR autophosphorylation in rat aorta smooth muscle cells.
• A Soluble Base for the Copper-Catalyzed Imidazole N-Arylations with Aryl Halides
  作者：Longbin Liu、Mike Frohn、Ning Xi、Celia Dominguez、Randy Hungate、Paul J. Reider

  DOI：10.1021/jo051640t

  日期：2005.11.1

  CuI-catalyzed N-arylation of imidazoles with aryl bromides has been achieved in a near-homogeneous system that utilizes tetraethylammonium carbonate as base, 8-hydroxy-quinoline as ligand, and H2O as cosolvent. Preliminary results with aryl chlorides are also reported.